Document Detail


A 6-month prospective study on efficacy safety and QOL profiles of extended-release formulation of valproate in patients with epilepsy.
MedLine Citation:
PMID:  20951067     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The goals of this study were to evaluate the efficacy, safety, and quality of life profiles of ER formulation of valproate in patients with epilepsy. This was a prospective, multicentre, open-lable study. Patients with a definite diagnosis of epilepsy were included and prescribed the ER formulation of valproate as initial or add-on therapy for 6 months. Efficacy and safety re-evaluation procedures were performed at 1 (V1), 3 (V2), and 6 months (V3) after enrollment. A QOLIE-31 inventory was used to assess the quality of life before and after the 6-month treatment. Nine hundred and fifty-eight patients with diagnosis of epilepsy were included in the analysis. The mean of seizure frequency at baseline was 8.56 per month. The median maintenance dose of the ER valproate was 750 mg per day. The number of seizure attacks per month was significantly decreased at the last visit compared to baseline by 88.3%. Patients improved quality of life in the fields of 'seizure worry' (P=0.000), 'overall quality of life' (P=0.000), 'social function' (P<0.01), and 'Question 31' (P=0.000), but showed decreased 'energy' (P=0.000). In the early phase of treatment, the main adverse effects included drowsiness, dizziness, and anorexia. By 6 months of treatment, weight gain, alopecia, and tremor were most frequently reported. The results of the present study demonstrated that patients receiving ER valproate as add-on or mono-therapy for 6 months exhibited significantly greater median percent reductions from baseline in seizure frequency for all seizure types, and significantly higher responder rates and higher seizure freedom rates, with good tolerance and improved quality of life.
Authors:
Pei-min Yu; Guo-xing Zhu; Xun-yi Wu; Ting Li; Lan Xu; Li Yue; Bei Wang; Zhen Hong
Related Documents :
20024887 - Long-term follow-up of a non-infantile desmoplastic ganglioglioma.
2330077 - Surgical excision of cerebral arteriovenous malformations: late results.
19389077 - The first japanese patient with variant creutzfeldt-jakob disease (vcjd).
15066547 - Postoperative eeg and seizure outcome in temporal lobe epilepsy surgery.
9788107 - Experience with the ultrex and ultrex plus inflatable penile prosthesis: new implantati...
1347857 - Effect of calcitonin-gene-related peptide in patients with delayed postoperative cerebr...
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2010-10-14
Journal Detail:
Title:  Seizure     Volume:  20     ISSN:  1532-2688     ISO Abbreviation:  Seizure     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-01-03     Completed Date:  2011-11-09     Revised Date:  2014-10-21    
Medline Journal Info:
Nlm Unique ID:  9306979     Medline TA:  Seizure     Country:  England    
Other Details:
Languages:  eng     Pagination:  23-6     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Chemistry, Pharmaceutical
Child
Delayed-Action Preparations / administration & dosage,  adverse effects
Epilepsy / drug therapy*,  psychology*
Female
Gastrointestinal Diseases / chemically induced
Humans
Male
Middle Aged
Prospective Studies
Quality of Life / psychology*
Treatment Outcome
Valproic Acid / administration & dosage*,  adverse effects*
Young Adult
Chemical
Reg. No./Substance:
0/Delayed-Action Preparations; 614OI1Z5WI/Valproic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Epilepsy surgery of posterior quadrant dysplasia in the first year of life: experience of a single c...
Next Document:  Intravital Imaging Reveals Distinct Dynamics for Natural Killer and CD8(+) T Cells during Tumor Regr...